JP2021515032A5 - - Google Patents
Info
- Publication number
- JP2021515032A5 JP2021515032A5 JP2020566524A JP2020566524A JP2021515032A5 JP 2021515032 A5 JP2021515032 A5 JP 2021515032A5 JP 2020566524 A JP2020566524 A JP 2020566524A JP 2020566524 A JP2020566524 A JP 2020566524A JP 2021515032 A5 JP2021515032 A5 JP 2021515032A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- antibody
- combination drug
- drug according
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023173684A JP2024009886A (ja) | 2018-02-17 | 2023-10-05 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631771P | 2018-02-17 | 2018-02-17 | |
| US62/631,771 | 2018-02-17 | ||
| US201862757729P | 2018-11-08 | 2018-11-08 | |
| US62/757,729 | 2018-11-08 | ||
| PCT/US2019/018377 WO2019161320A1 (en) | 2018-02-17 | 2019-02-17 | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023173684A Division JP2024009886A (ja) | 2018-02-17 | 2023-10-05 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515032A JP2021515032A (ja) | 2021-06-17 |
| JPWO2019161320A5 JPWO2019161320A5 (https=) | 2022-03-09 |
| JP2021515032A5 true JP2021515032A5 (https=) | 2022-03-09 |
Family
ID=67620025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566524A Pending JP2021515032A (ja) | 2018-02-17 | 2019-02-17 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
| JP2023173684A Pending JP2024009886A (ja) | 2018-02-17 | 2023-10-05 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023173684A Pending JP2024009886A (ja) | 2018-02-17 | 2023-10-05 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200405719A1 (https=) |
| EP (1) | EP3752528A4 (https=) |
| JP (2) | JP2021515032A (https=) |
| CN (1) | CN112424222A (https=) |
| CA (1) | CA3091373A1 (https=) |
| WO (1) | WO2019161320A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3091373A1 (en) * | 2018-02-17 | 2019-08-22 | Apollomics Inc. | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint |
| JP2023523295A (ja) * | 2020-04-26 | 2023-06-02 | アポロミクス インコーポレイテッド | Ｃ－ｍｅｔ阻害剤のための新規医薬製剤 |
| EP4159238A4 (en) * | 2020-06-02 | 2024-08-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY |
| CN113105436B (zh) * | 2021-04-20 | 2022-07-01 | 西格莱(苏州)生物医药有限公司 | 吡唑类化合物的制备方法及其中间体 |
| WO2023172629A2 (en) * | 2022-03-08 | 2023-09-14 | Brown University | Anticancer maleimide derivatives for use with immune checkpoint blockade |
| WO2025129332A1 (en) * | 2023-12-21 | 2025-06-26 | 11949098 Canada Inc. (Nuredco) C/O Jean I. Tchervenkov | Method of prognosis and monitoring of cancer patient and of determining immunological status of a subject |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| EP3122900A1 (en) * | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| KR102524920B1 (ko) * | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| US10435470B2 (en) * | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| AU2015327868A1 (en) * | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| TWI695837B (zh) * | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
| RS61152B2 (sr) * | 2015-05-12 | 2024-06-28 | Hoffmann La Roche | Terapeutski i dijagnostički postupci za lečenje raka |
| CA3000386A1 (en) * | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| HK1254635A1 (zh) * | 2015-12-17 | 2019-07-26 | Novartis Ag | C-met抑制剂与pd-1抗体分子的组合及其用途 |
| CA3091373A1 (en) * | 2018-02-17 | 2019-08-22 | Apollomics Inc. | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint |
| EP4159238A4 (en) * | 2020-06-02 | 2024-08-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY |
-
2019
- 2019-02-17 CA CA3091373A patent/CA3091373A1/en active Pending
- 2019-02-17 CN CN201980026429.9A patent/CN112424222A/zh active Pending
- 2019-02-17 US US16/970,384 patent/US20200405719A1/en not_active Abandoned
- 2019-02-17 WO PCT/US2019/018377 patent/WO2019161320A1/en not_active Ceased
- 2019-02-17 JP JP2020566524A patent/JP2021515032A/ja active Pending
- 2019-02-17 EP EP19754620.3A patent/EP3752528A4/en not_active Withdrawn
-
2023
- 2023-10-05 JP JP2023173684A patent/JP2024009886A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515032A5 (https=) | ||
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2012515776A5 (https=) | ||
| RU2013130250A (ru) | Замещенные пуриновые и 7-деазапуриновые соединения | |
| JP2016506958A5 (https=) | ||
| JP2018502902A5 (https=) | ||
| JP2021532162A5 (https=) | ||
| JP2017533266A5 (https=) | ||
| TR201809990T4 (en) | NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING. | |
| RU2014140735A (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2018530554A5 (https=) | ||
| JP2015534574A5 (https=) | ||
| PE20220935A1 (es) | Quelantes macrociclicos y metodos de uso de estos | |
| JP2016508130A5 (https=) | ||
| EP4329431A3 (en) | Novel heteroleptic iridium complexes | |
| RU2021102253A (ru) | Деструкторы белка mdm2 | |
| JP2015535277A5 (https=) | ||
| JP2013544846A5 (https=) | ||
| JP2017510660A5 (https=) | ||
| RU2018105614A (ru) | Производное 1,3,5-триазина и способ его применения | |
| EA201890094A1 (ru) | Производные полициклических амидов в качестве ингибиторов cdk9 | |
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| RU2014145121A (ru) | Пиримидиновые соединения для лечения злокачественной опухоли | |
| EA201490580A1 (ru) | Пирролбензодиазепины и их конъюгаты | |
| FI3795592T3 (fi) | Vasta-aineiden, jotka sitovat lymfosyyttejä aktivoivaa geeni-3:a (lag-3), optimointi ja niiden käytöt |